Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases
A cutting-edge study from the University of California, San Francisco, recently showed that researchers have been able to make immune cells, which already recognize cancer cells, more powerful and durable through CRISPR gene editing tools, promising to become tireless, cold-blooded "cancer killers"!
Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.
A study at Massachusetts General Hospital in the US demonstrated that Adagrasib alone and in combination with cetuximab delivered good results in patients with advanced colorectal cancer with KRAS G12C mutations, with 46% of subjects experiencing substantial tumour shrinkage and an efficacy rate of 100%.
A new study shows that for a common type of skin cancer, squamous cell carcinoma of the skin, immunotherapy before surgery resulted in the complete disappearance of tumours in 50.6% of patients and more than 90% in 12.7% of patients.
UniversityClinic Hamburg-Eppendorf, UKE was founded on 17 May 1889 in Hamburg, Germany's second largest city, and is one of Europe's leading hospitals and the NO.1 medical centre of its size in Hamburg.
Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!
The University of Washington Medical Center owns and manages CUMG and the Seattle Cancer Care Alliance, which is a joint venture between the University of Washington Medical Center, Fred Hutchinson Cancer Research Center and Seattle Children's Hospital.
A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.
DZD1516 is a reversible, selective HER2-targeting agent with full blood-brain barrier penetration. It has demonstrated good therapeutic response in phase I studies in patients with metastatic HER2-positive breast cancer, including breast cancer patients with central nervous system metastases.
